[1] Shida D, Kitayama J, Yamagnchi H, et al. Lysophosphatidic acid enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1[J]. Cancer Res, 2003, 63(7): 1706-11. [2] Fish DA, Liu Y, Shawn M, et al. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarion cancer cells[J]. Cancer Res, 2001, 61 (7): 3194-9. [3] Hu YL, Tee MK,Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovariancancer cells[J]. J Natl Cancer Inst, 2001, 93: 762-8. [4] Gordon B, Wouter M, Moolenaar H. The emerging role of lysophosphatidic acid in cancer[J]. Nature, 2003, 3: 582-91. [5] Xu Y, Gaudette DC, Bpynton JD, et al. Characterization of an ovarion cancer activating in ascites from ovarion cancer patients[J].Clin Cancer Res, 1995, 1: 1223-313. [6] Fang X, Yu SX, Robert C, et al. Mechanisms for Lysophosphatidic acid-induced cytokion production in ovarian cancer cells[J]. J Biol Chem, 2004, 279(10): 9651-61. [7] Hu YL, Albanese CH, Pestell RG, et al. Dual mechanisms for Lysophosphatidic acid stimulation of human ovarian carcinoma cells[J].Cancer Invest, 2003, 95(10): 733-40. [8] Shida D, Watanabe t, Aoki J, et al. Aberrant expression of lysophosphatidic acid receptors in human colorectal cancer[J]. Lab Invest,2004, 1-11. [9] Yamada T, Sato K, Komach M, et al. Lysophosphatidic acid (LPA)in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1[J]. Biol Chem, 2004, 279(8): 6595-605. [10] Fujita T, Miyamoto S, Onoyama I, et al. Expression lysophosphatidic acid receptors and vascular endothelia growth factor mediating lysophosphatidic acid in the development of human ovarian cancer[J]. Cancer Lett, 2003, 192: 161-9. |